Intranasal Ketamine for Late-Life Depression and Suicidal Ideation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02295787|
Recruitment Status : Withdrawn (No funding)
First Posted : November 20, 2014
Last Update Posted : March 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Depression Suicide Suicidal Ideation||Drug: Ketamine Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Intranasal Ketamine for Late-Life Depression and Suicidal Ideation|
|Study Start Date :||July 2015|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||July 2015|
Intranasal Ketamine 50mg administered six times over three weeks.
Intranasal ketamine for late-life depression and suicidal ideation.
Placebo Comparator: Placebo
Intranasal saline solution administered six times over three weeks.
- Hamilton Depression Rating Scale (HDRS) [ Time Frame: Up to 4 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02295787
|Principal Investigator:||Dawn F Ionescu, MD||Massachusetts General Hospital|